Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world data.
Shigeo ShimoseRie SugimotoAtsushi HiraokaMasatoshi TanakaHideki IwamotoYuki TanakaFujimasa TadaHideko OhamaTakashi NiizekiTomotake ShironoEtsuko MoriyamaYu NodaNaoki KamachiMasahito NakanoRyoko KuromatsuHironori KogaTakumi KawaguchiPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)
The therapeutic effect of RAM increased in patients with Atezo/Beva failure. Patients with splenomegaly and low BMI should be monitored for ascites during RAM treatment.